Search Thermo Fisher Scientific
Connecting patients everywhere to precision oncology
In the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients. Unfortunately, the lengthy wait for next-generation sequencing (NGS) results—often weeks—and the risk of insufficient sample quantity (QNS) can diminish this hope. The newly FDA-approved Oncomine Dx Express Test is set to revolutionize this process. Capable of being implemented in even labs without NGS expertise close to patients, it delivers results within just 24 hours, from tissue sample to report.
Rapid means as little as 24 hours, from patient sample to report
The Oncomine Dx Express Test can eliminate the lengthy wait for a complete biomarker picture. It enables pathology labs to deliver results in as little as 24 hours, facilitating faster, more informed treatment decisions so that your patients don't have to wait weeks for results.
Precision oncology close to the patients
The Oncomine Dx Express Test is designed for implementation in local laboratories, enabling in-house testing. This supports timely, decentralized precision oncology by delivering NGS results close to patients.
Quantity not sufficient is not an answer for the patient
The Oncomine Dx Express Test requires only 10 ng of DNA and RNA, which is significantly less sample input than other NGS technologies and therefore is more efficient even with challenging samples and small biopsies.
Table 1. Companion diagnostic indications
Tissue type |
Gene |
Variant |
Targeted therapy |
Non-small cell lung cancer (NSCLC) |
EGFR |
EGFR exon 20 insertions |
ZEGFROVY™ (sunvozertinib) |
Table 2. Oncomine Dx Express Test panel gene list
DNA |
RNA |
|||||||||
Substitutions, insertions, and deletions |
Copy number variants |
Fusions and splice variants |
||||||||
AKT1 AKT2 AKT3 ALK AR ARAF BRAF |
CDK4 CHEK2 CTNNB1 EGFR ERBB2 ERBB3 ERBB4 |
ESR1 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 GNAS |
HRAS IDH1 IDH2 KEAP1 KIT KRAS MAP2K1 |
MAP2K2 MET NRAS NTRK1 NTRK2 NTRK3 PDGFRA |
PIK3CA PTEN RAF1 RET ROS1 STK11 TP53 |
AR EGFR ERBB2 ERBB3 FGFR1 |
FGFR2 FGFR3 KRAS MET PIK3CA |
ALK AR BRAF EGFR ESR1 FGFR1 |
FGFR2 FGFR3 MET NRG1 NTRK1 NTRK2 |
NTRK3 NUTM1 RET ROS1 RSPO2 RSPO3 |
NGS made easy—2 instruments, 1 software, and as little as 20 minutes of hands-on time
The Genexus Dx System automates the NGS workflow from patient samples to reports with only two user touchpoints and as little as 20 minutes of hands-on time.
Pre-treated FFPE tissue sections are loaded onto the Genexus Dx Purification System and the instrument performs automated purification and quantification of DNA and RNA.
Library preparation, template preparation, sequencing, analysis, and reporting are performed by the Genexus Dx Integrated Sequencer. Throughout this procedure, sample and reagent information is recorded and tracked by one integrated software. This highly automated workflow helps reduce laboratory staff burden and the potential for human errors and alleviates the need for specialized bioinformatics expertise.
Oncomine Dx Express Test workflow
For In Vitro Diagnostic Use.
CN: 63025